Biogen Inc (BIIB)

What to do with $40 billion? That is the question facing Allergan (AGN). One biotechnology stock which stands out as a potential target for Allergan is Applied Genetic Technologies (AGTC).

Apple's iPhone 7 launch has surprised the skeptics

A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTA TM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking...

Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2016 financial results on Wednesday, October 26, 2016, before the financial markets open.

Stocks lose highs by mid-afternoon Wednesday as a selloff in crude resumes.

U.S. stocks bounced around in the green in far more stable trading following three days of extreme swings.

Stocks add to slight gains on Wednesday as Wall Street stabilizes after three days of extreme swings.

Biogen (BIIB) reported Wednesday that Tecfidera, its multiple sclerosis treatment, had positive results in recent clinical and real world trials.

New real-world and clinical evidence demonstrates that TECFIDERA ® (dimethyl fumarate) consistently delivered strong, sustained efficacy in newly-diagnosed and previously treated patients with relapsing-remitting...

New research collected from more than 16,000 multiple sclerosis (MS) patients across Europe, in the largest study to capture the widespread impact of the disease, along with updated clinical findings from the company's...

Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.

Check out this biotech ETF, and Biogen, for plays on any recovery.

Stocks hold mixed by mid-morning Tuesday after U.S. services activity last month declines more than expected.

Stock futures edge higher in the return from the long Labor Day weekend as markets continue to mull over the Federal Reserve's next big move.

Here are Tuesday's top research calls, including an upgrade for Gilead Sciences, downgrades for Biogen and VF Corp., and new coverage for CBS.

Biogen's (BIIB) stock rating was cut to 'hold' from 'buy' at Jefferies on Tuesday morning.

Biogen is up 2% year to date, and it would have been down more if not for a 40% move off the bottom.

Biogen (BIIB) stock was up Friday morning after the FDA fast-tracked its Alzheimer's drug.

Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for early Alzheimer's disease (AD), was granted Fast Track designation by the U.

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference.

Results from pre-clinical research and PRIME, the Phase 1b study of Biogen's (NASDAQ: BIIB) investigational treatment for early Alzheimer's disease (AD), aducanumab, were published today in Nature.

Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.

Biogen's pullback should drag shares lower into a low-risk buy zone.

The leadership is quite stark.

Hedge fund managers continue to flee stocks in the second quarter, but the smart money eyed several potential opportunities, including Charter Communications and Morgan Stanley.

A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.

RBC Capital analysts say this would free 'trapped value' on drug treatments.

Besides Tesla, Twitter and Biogen make good candidates.